Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHB3 | P54753 | 3/20 | 0.58 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 5/20 | 0.42 |
| ▸ | NPC1 | O15118 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | EIF4A3 | P38919 | 5/20 | 0.39 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24369876 | 0.86 | EPHB3 (0.58) | EPHB3HTR2AHTR2CRAB9ANPC1 | |
| SCHEMBL30977391 | 0.84 | EPHB3 (0.56) | EPHB3HTR2AHTR2CRAB9ANPC1 | |
| SCHEMBL17453567 | 0.81 | NPC1 (0.43) | EPHB3MAPK1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL3083798 | 0.81 | EPHB3 (0.57) | EPHB3MAPK1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL24369875 | 0.81 | EPHB3 (0.50) | EPHB3MAPK1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL17323234 | 0.77 | LCK (0.46) | EPHB3MAPK1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL26765489 | 0.77 | EPHB3 (0.58) | EPHB3MAPK1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL17453430 | 0.76 | EIF4A3 (0.43) | EPHB3RAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL17454436 | 0.74 | NPC1 (0.39) | EPHB3RAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL2288826 | 0.74 | JAK1 (0.45) | EPHB3HTR2AHTR2CRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2176260-A1 | PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-04-21 | — | — | EP | claimed |
| WO-2009008748-A1 | PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-01-15 | — | — | WO | claimed |
| US-20100226881-A1 | PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-09-09 | — | — | US | disclosed |
| EP-2176260-A1 | PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-04-21 | — | — | EP | disclosed |
| WO-2009008748-A1 | PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100226881-A1 | PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY | TP53, PNPO, DPYD | EPHB3 2757/4885HTR2A 2819/4885HTR2C 2275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.